Title: Amendment - 1st Reading-white - Requested by: Dennis Lenz - (S) Public Health, Welfare
Official Title: Amendment - 1st Reading-white - Requested by: Dennis Lenz - (S) Public Health, Welfare
Number of Sections: 1
Source: versions - SB0317.001.001_Amendments-in-Context_final-full.pdf
Media Type: application/pdf
Strikethrough Detection: 2 sections found

================================================================================

Section 1:
and Safety
- 2025
69th Legislature 2025 Drafter: Chanan Brown, SB0317.001.001
1 SENATE BILL NO. 317
2 INTRODUCED BY D. LENZ
3
4 A BILL FOR AN ACT ENTITLED: “AN ACT PROHIBITING HEALTH INSURANCE ISSUERS FROM
5 PERFORMING PRIOR AUTHORIZATION ON PSYCHIATRIC DRUGS THAT ARE IN SHORTAGE OR
6 DISCONTINUED; AND AMENDING SECTION 33-32-221, MCA.”
7
8 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:
9
10 Section 1. Section 33-32-221, MCA, is amended to read:
11 "33-32-221. Prior authorization requirements. (1) A health insurance issuer may not perform prior
12 authorization on benefits for:
13 (a) any generic prescription drug that is not listed within any of the schedules of controlled
14 substances found at 21 CFR 1308.11 through 21 CFR 1308.15 or the schedules of controlled substances found
15 in Title 50, chapter 32, after a covered person has been prescribed the covered drug at the same quantity
16 without interruption for 6 months;
17 (b) any prescription drug or drugs, generic or brand name, on the grounds of therapeutic
18 duplication for the same drug if the covered person has already been subject to prior authorization on the
19 grounds of therapeutic duplication for the same dosage of the prescription drug or drugs and coverage of the
20 prescription drug or drugs was approved;
21 (c) any prescription drug, generic or brand name, solely because the dosage of the medication for
22 the covered person has been adjusted by the prescriber of the prescription drug, as long as the dosage is
23 within the dosage approved by the food and drug administration or is consistent with clinical dosing for the
24 medication; or
25 (d) any prescription drug, generic or brand name, that is a long-acting injectable antipsychotic; or
26 (e) any prescription drug, generic or brand name, that is designated as currently in shortage within
27 the therapeutic category of psychiatry on the current and resolved drug shortages and discontinuations list
- 1 - Authorized Print Version – SB 317
Amendment - 1st Reading-white - Requested by: Dennis Lenz - (S) Public Health, Welfare
and Safety
- 2025
69th Legislature 2025 Drafter: Chanan Brown, SB0317.001.001
1 maintained by the United States food and drug administration.
2 (e) any prescription drug, generic or brand name, that is designated as in shortage pursuant to
3 subsection (3).
4 (2) Any adverse determination for a prescription drug made during prior authorization by a health
5 insurance issuer must be made by a physician whose specialty focuses on the diagnosis and treatment of the
6 condition for which the prescription drug was prescribed to treat, provided that prior authorization that does not
7 result in an adverse determination does not require the involvement of a physician on the part of a health
8 insurance issuer.
9 (3) (a) For the purposes of subsection (1)(e), the list of prescription drugs within the therapeutic
10 category of psychiatry that are in shortage on April 1, July 1, October 1, or January 1 must be determined
11 directly from the official shortage list published by the United States food and drug administration on those
12 dates. The quarterly static list remains in effect until the next quarterly date.
13 (b) A manufacturer of a prescription drug subject to subsection (1)(e) may not engage in predatory
14 pricing or marketing related to any shortage described in this section. A violation of this subsection (3)(b) is
15 subject to enforcement and penalty under Title 30, chapter 14, part 1."
16 - END -
- 2 - Authorized Print Version – SB 317
[DELETED:  D S- SIAPDB0S1" P2a3()a4s5i6w7()a8d9g0p1()a2t3w4m5()a6()a7t]
[DELETED:  D S- m()as()Aicri()(0c1d2d3()A4p5s6-]


================================================================================

Raw Text:
Amendment - 1st Reading-white - Requested by: Dennis Lenz - (S) Public Health, Welfare
and Safety
- 2025
69th Legislature 2025 Drafter: Chanan Brown, SB0317.001.001
1 SENATE BILL NO. 317
2 INTRODUCED BY D. LENZ
3
4 A BILL FOR AN ACT ENTITLED: “AN ACT PROHIBITING HEALTH INSURANCE ISSUERS FROM
5 PERFORMING PRIOR AUTHORIZATION ON PSYCHIATRIC DRUGS THAT ARE IN SHORTAGE OR
6 DISCONTINUED; AND AMENDING SECTION 33-32-221, MCA.”
7
8 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:
9
10 Section 1. Section 33-32-221, MCA, is amended to read:
11 "33-32-221. Prior authorization requirements. (1) A health insurance issuer may not perform prior
12 authorization on benefits for:
13 (a) any generic prescription drug that is not listed within any of the schedules of controlled
14 substances found at 21 CFR 1308.11 through 21 CFR 1308.15 or the schedules of controlled substances found
15 in Title 50, chapter 32, after a covered person has been prescribed the covered drug at the same quantity
16 without interruption for 6 months;
17 (b) any prescription drug or drugs, generic or brand name, on the grounds of therapeutic
18 duplication for the same drug if the covered person has already been subject to prior authorization on the
19 grounds of therapeutic duplication for the same dosage of the prescription drug or drugs and coverage of the
20 prescription drug or drugs was approved;
21 (c) any prescription drug, generic or brand name, solely because the dosage of the medication for
22 the covered person has been adjusted by the prescriber of the prescription drug, as long as the dosage is
23 within the dosage approved by the food and drug administration or is consistent with clinical dosing for the
24 medication; or
25 (d) any prescription drug, generic or brand name, that is a long-acting injectable antipsychotic; or
26 (e) any prescription drug, generic or brand name, that is designated as currently in shortage within
27 the therapeutic category of psychiatry on the current and resolved drug shortages and discontinuations list
- 1 - Authorized Print Version – SB 317

Amendment - 1st Reading-white - Requested by: Dennis Lenz - (S) Public Health, Welfare
and Safety
- 2025
69th Legislature 2025 Drafter: Chanan Brown, SB0317.001.001
1 maintained by the United States food and drug administration.
2 (e) any prescription drug, generic or brand name, that is designated as in shortage pursuant to
3 subsection (3).
4 (2) Any adverse determination for a prescription drug made during prior authorization by a health
5 insurance issuer must be made by a physician whose specialty focuses on the diagnosis and treatment of the
6 condition for which the prescription drug was prescribed to treat, provided that prior authorization that does not
7 result in an adverse determination does not require the involvement of a physician on the part of a health
8 insurance issuer.
9 (3) (a) For the purposes of subsection (1)(e), the list of prescription drugs within the therapeutic
10 category of psychiatry that are in shortage on April 1, July 1, October 1, or January 1 must be determined
11 directly from the official shortage list published by the United States food and drug administration on those
12 dates. The quarterly static list remains in effect until the next quarterly date.
13 (b) A manufacturer of a prescription drug subject to subsection (1)(e) may not engage in predatory
14 pricing or marketing related to any shortage described in this section. A violation of this subsection (3)(b) is
15 subject to enforcement and penalty under Title 30, chapter 14, part 1."
16 - END -
- 2 - Authorized Print Version – SB 317

[DELETED:  D S- SIAPDB0S1" P2a3()a4s5i6w7()a8d9g0p1()a2t3w4m5()a6()a7t]
[DELETED:  D S- m()as()Aicri()(0c1d2d3()A4p5s6-]